MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected

MindMed’s MNMD Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. 

“We have seen a meaningful acceleration in enrollment over the last few months since our full set of study sites were activated early this year with 25 patients enrolled just in the last 30 days,” said director and CEO Robert Barrow of the clinical-stage biopharma company.

He added that the company is “thrilled by the quality and efficiency” with which study enrollment has progressed, calling it “a testament to the tireless work and dedication” of those executing the study and “one of the fastest recruiting efforts” in psychedelic-assisted therapy trials. 

The multi-center Phase 2b study intends to enroll up to 200 participants diagnosed with GAD, who will be randomized to receive a single administration of either 200, 100, 50 or 25 micrograms of MM-120 or placebo. 

The trial’s primary goal is to determine the reduction in anxiety symptoms 4 weeks after the drug administration compared across the five patient groups, with secondary outcomes (including assessments of anxiety symptoms, safety and tolerability and additional measures of efficacy and quality of life) in a follow-up period of 12 weeks post-dose.

MindMed expects to announce its topline results of the study in late 2023.

See the company’s financial results and business highlights for the first quarter of 2023 and the uprising around the upcoming management elections.

Photo: Benzinga edit with photo by Kat Smith on Pexels and Jü on Wikipedia.